Journal of the American Society of Nephrology· 2017Q1
Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients
- 251citations
- Q1SCImago
- 2017year
Short summary
Kidney transplant recipients with de novo donor-specific antibodies (DSA) at rejection show worse graft survival (34% at 8 years) compared to those with preexisting DSA (63%), despite similar C4d deposition and peritubular capillaritis.
AI-generated from the title and abstract; the full text is not read.
Key points
- De novo DSA ABMR showed increased proteinuria and transplant glomerulopathy compared to preexisting DSA ABMR.
- Gene expression differed, with de novo DSA ABMR showing increased IFNγ and NK/T cell transcripts, and decreased AKI transcripts.
- Graft survival at 8 years post-rejection was significantly lower for de novo DSA ABMR (34%) versus preexisting DSA ABMR (63%).
- Independent risk factors for allograft loss included de novo DSA ABMR, low eGFR, high proteinuria, and transplant glomerulopathy.
AI-generated from the title and abstract; the full text is not read.
Abstract
Antibody-mediated rejection (ABMR) can occur in patients with preexisting anti-HLA donor-specific antibodies (DSA) or in patients who develop de novo DSA. However, how these processes compare in terms of allograft injury and outcome has not been addressed. From a cohort of 771 kidney biopsy specimens from two North American and five European centers, we performed a systematic assessment of clinical and biologic parameters, histopathology, circulating DSA, and allograft gene expression for all patients with ABMR ( n =205). Overall, 103 (50%) patients had preexisting DSA and 102 (50%) had de novo DSA. Compared with patients with preexisting DSA ABMR, patients with de novo DSA ABMR displayed increased proteinuria, more transplant glomerulopathy lesions, and lower glomerulitis, but similar levels of peritubular capillaritis and C4d deposition. De novo DSA ABMR was characterized by increased expression of IFN γ -inducible, natural killer cell, and T cell transcripts, but less expression of AKI transcripts compared with preexisting DSA ABMR. The preexisting DSA ABMR had superior graft survival compared with the de novo DSA ABMR (63% versus 34% at 8 years after rejection, respectively; P <0.001). After adjusting for clinical, histologic, and immunologic characteristics and treatment, we identified de novo DSA ABMR (hazard ratio [HR], 1.82 compared with preexisting DSA ABMR; 95% confidence interval [95% CI], 1.07 to 3.08; P =0.03); low eGFR (<30 ml/min per 1.73 m 2 ) at diagnosis (HR, 3.27; 95% CI, 1.48 to 7.23; P <0.001); ≥0.30 g/g urine protein-to-creatinine ratio (HR, 2.44; 95% CI, 1.47 to 4.09; P <0.001); and presence of cg lesions (HR, 2.25; 95% CI, 1.34 to 3.79; P =0.002) as the main independent determinants of allograft loss. Our findings support the transplant of kidneys into highly sensitized patients and should encourage efforts to monitor patients for de novo DSA.
The authors' abstract, as published at the source. Journal of the American Society of Nephrology, 2017 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Transplantation
TransplantationMedicine